Influvac (Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic)

The vaccine contains inactivated antigens from selected influenza B and A strains. After injection, the antigens are taken up by immune cells, prompting the body to produce strain‑specific antibodies and activate T‑cell responses, thereby establishing active immunity that can neutralise the targeted viruses.

The prescribed dose of Influvac is determined by a qualified healthcare professional based on the patient’s age, health status, and local immunization guidelines. The prescriber will select the appropriate volume and administration route for each individual.

Influvac may be administered to pregnant or breastfeeding individuals when the potential benefits outweigh any theoretical risks. Healthcare providers should evaluate each case, as the vaccine is generally considered safe but formal safety data are limited, and a risk‑benefit assessment is essential.

To place an order, submit an enquiry on the Influvac product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Influvac contains the specific B/Austria/1359417/2021‑like and A/Vic strains recommended for the current season, similar to other quadrivalent or trivalent vaccines. Differences may lie in the exact strain composition, manufacturing process, and regulatory approvals, but all aim to induce protective immunity against circulating influenza viruses.

Influvac must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The vaccine should be kept in its original packaging until use to maintain potency and stability throughout distribution.

Influvac is administered by a trained healthcare professional via intramuscular or subcutaneous injection, typically into the deltoid muscle of the upper arm. The injection site should be cleaned with an antiseptic, and the dose is delivered using a sterile needle and syringe.

The most serious risks include severe allergic reactions such as anaphylaxis, Guillain‑Barré syndrome, high fever, seizures, and immune‑mediated thrombocytopenia. Patients should be observed for a short period after vaccination and seek immediate medical attention if any severe symptoms develop.

Influvac should not be given to individuals with a known severe allergy to any component of the vaccine or to those who have experienced a serious reaction to a previous influenza vaccine. It should also be avoided in persons with active, uncontrolled acute illness until they recover.